Xortx highlights achievements of 2023 and preparation for registration clinical trial

Calgary, alberta, march 19, 2024 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anua wkn: a3unz), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to provide a summary of company's achievements in 2023 and objectives planned for 2024.
XRTX Ratings Summary
XRTX Quant Ranking